Clinical trials: Pulmonary Artery Hypertension
Hypertension, Pulmonary
A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)
GSK2586881, a purified intravenous (IV) formulation of soluble recombinant human Angiotensin Converting Enzyme (rhACE2) is being investigated as a treatment for PAH.
- Trial name
- NCT03177603
- Testing
- GSK2586881
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Idiopathic Pulmonary Arterial Hypertension
Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension
Experimental data suggest that transplantation of endothelial progenitor cells (EPCs) attenuates monocrotaline-induced pulmonary hypertension in rats and dogs.
- Trial name
- NCT00257413
- Testing
- Transplantation of autologous endothelial progenitor cells
- Where
- China
- Sponsor
- Zhejiang University
Pulmonary Arterial Hypertension
Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States
The Opsumit Users registry (OPUS; NCT02126943) was developed to characterize the safety profile of Opsumit and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing…
- Trial name
- OrPHeUS (NCT03197688)
- Testing
- Notapplicable
- Where
- 106 sites in United States, Puerto Rico
- Volunteers
- 2,200 people
- Sponsor
- Actelion
Chronic Obstructive Pulmonary Disease, Hypertension, Pulmonary
Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults (DHEA-HTAP)
DHEA prevents and reverses chronic hypoxic pulmonary hypertension in a chronic hypoxic-pulmonary hypertension model in the rat. However, no study has been performed in human.
- Trial name
- Dromer (NCT01273259)
- Testing
- DHEA Treatment
- Where
- 4 sites in France
- Volunteers
- 51 people
- Sponsor
- University Hospital, Bordeaux
Sickle Cell Disease
Epidemiology and Pathophysiological Mechanisms of HTAP in SS and SC Children in Martinique and Guadeloupe.
pulmonary arterial hypertension (PAH) has been reported with a prevalence of approximately 30% in adult sickle cell disease (SCD) patients, with an increased mortality in SCD patients with PAH, compared with those without PAH.
- Trial name
- SAPOTILLE (NCT03368261)
- Testing
- HTAP/ clinical complications in the sickle cell disease
- Where
- Martinique
- Volunteers
- 185 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Hypertension, Pulmonary
Atorvastatin in Pulmonary Hypertension
Clinical effect and tolerability of atorvastatin versus placebo in patients with Pulmonary Hypertension: double-blinded, randomised, prospective phase II study for 6 months with adjusted doses of Atorvastatin
- Trial name
- APATH (NCT00615823)
- Testing
- Atorvastatin
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Idiopathic Pulmonary Arterial Hypertension
Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension
Experimental data suggest that transplantation of endothelial progenitor cells (EPCs) attenuates monocrotaline-induced pulmonary hypertension in rats and dogs.
- Trial name
- NCT00372346
- Testing
- Transplantation of autologous endothelial progenitor cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Pulmonary Arterial Hypertension
FUTURE 3 Study Extension
The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension…
- Trial name
- FUTURE 3 Ext (NCT01338415)
- Testing
- Bosentan
- Where
- 36 sites in United States, Australia and 16 more
- Volunteers
- 58 people
- Sponsor
- Actelion
Pregnancy Related, Fetal; Circulation
Doppler Ultrasonographic Assessment of Fetal Internal Thoracic Artery Indexes
The aim of this study is to assess the feasibility of visualizing the internal thoracic artery (ITA), establishing the normogram for ITA pulsatility index (PI), resistance index (RI) and acceleration/ejection time (AT/ET) at…
- Trial name
- NCT04686240
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Ankara City Hospital Bilkent
Pulmonary Arterial Hypertension
TReatment Of Pulmonary HYpertension 1-US Study
The objective of this study is to assess the safety, performance and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation through subjective and objective change in clinical parameters and…
- Trial name
- TROPHY 1-US (NCT02835950)
- Testing
- Therapeutic Intra-Vascular UltraSound (TIVUS™) System
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- SoniVie Inc.
Sarcoidosis, Pulmonary Arterial Hypertension
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
This trial will study the treatment of sarcoidosis-associated pulmonary arterial hypertension with inhaled iloprost, a drug approved for primary pulmonary arterial hypertension.
- Trial name
- NCT00403650
- Testing
- Iloprost
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Pulmonary Arterial Hypertension (PAH), Quality of Life
Development and Validation of a Chinese Quality of Life Scale for Pulmonary Arterial Hypertension
This study aims to develop and validate a culturally appropriate, reliable, and clinically applicable patient-reported outcome (PRO) instrument to assess quality of life in patients with pulmonary arterial hypertension (PAH) in…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Quality of Life, Patients Reported Outcomes
- Trial name
- NCT07570615
- Testing
- Questionnaire Assessment
- Volunteers
- 300 people
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Pulmonary Arterial Hypertension
Responsiveness of Exercise Tests in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is characterized by the progressive increase in pulmonary vascular resistance leading to shortness of breath and exercise intolerance.
- Trial name
- RESPONS (NCT01391104)
- Testing
- Sildenafil, Sugar Pill
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Laval University
Pulmonary Arterial Hypertension
TROPHY PAH Pivotal Study - TReatment of Pulmonary HYpertension for PAH Pivotal Study
Theis is a prospective, multicenter, blinded, randomized sham controlled pivotal clinical trial with a crossover at 6M, to assess the safety and effectiveness of pulmonary artery denervation with the TIVUS™ System in subjects…
- Trial name
- NCT04570228
- Testing
- Pulmonary artery denervation
- Volunteers
- 205 people
- Sponsor
- SoniVie Inc.
Pulmonary Arterial Hypertension
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
This is a multinational, multi center extension study. This study will provide data on the long-term safety, tolerability, and efficacy of imatinib in the treatment of severe pulmonary arterial hypertension.
- Trial name
- IMPRES Extn (NCT01117987)
- Testing
- Imatinib
- Where
- 59 sites in United States, Austria and 11 more
- Volunteers
- 144 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension
A multicenter, randomized, double-blind, placebo-controlled, phase II-III clinical trial to evaluate the efficacy and safety of the study drug in adult patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT06683040
- Testing
- Oxacom
- Where
- Russia
- Volunteers
- 260 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Pulmonary Arterial Hypertension, Right Heart Failure
Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension
This is a Phase 2, single-center, randomized placebo controlled trial of famotidine (an H2 receptor antagonist) in adults with pulmonary arterial hypertension.
- Trial name
- REHAB-PH (NCT03554291)
- Testing
- Famotidine 20 MG
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Washington
Pulmonary Arterial Hypertension
Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension
Dyspnea is a major symptom in pulmonary arterial hypertension and people with the same haemodynamic have generally different degree of dyspnea in pulmonary arterial hypertension.
- Trial name
- HYPER2 (NCT03810443)
- Testing
- Hyperventilation test
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Hypertension
Clinical Study of Adipose Derived Mesenchymal Stem Cells for Treatment of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a disease characterised by pathological changes in the pulmonary arteries leading to a progressive increase in pulmonary vascular resistance and pulmonary artery pressure.
- Trial name
- NCT04055415
- Testing
- adipose derived mesenchymal stem cells, Conventional drug therapy（expectorant，bronchodilator）
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Liaocheng People's Hospital
Pulmonary Arterial Hypertension
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.
- Trial name
- EmPATH (NCT06992440)
- Testing
- Empagliflozin 10 MG
- Where
- 3 sites in United States
- Volunteers
- 78 people
- Sponsor
- Gustavo A Heresi, MD, MS